THL Partners Acquires Majority Stake in Celerion at $1.8B Enterprise Value

Precision doesn’t make noise, but it moves markets when it shows up with receipts. Celerion just pulled in a majority investment from THL Partners, with H.I.G. Capital stepping out after its run, and the signal lands clean at about $1.8B in enterprise value, backed by roughly $150M in EBITDA, the kind of number that doesn’t argue for attention because it already has it.

Susan Thornton, Ph.D., CEO, built this with a level of focus that most companies talk about but rarely sustain, choosing depth over distraction while the CRO market stretched itself thin, locking Celerion into clinical pharmacology and bioanalytical sciences where early-phase and first-in-human trials quietly determine what survives and what fades out before the spotlight ever hits.

THL Partners didn’t move for optics or a headline cycle, they moved because Celerion sits exactly where time, data, and capital collide without compromise, and when early-stage trials run with precision instead of friction, pipelines don’t just move faster, they move smarter, turning what looks operational on the surface into something far closer to strategic leverage underneath.

The path forward doesn’t need dramatic narration to make sense, it leans into expanding clinical capacity, sharpening bioanalytical depth, and tightening the connection between execution and insight, because Celerion already operates across North America and Europe with a system that links clinical environments to lab intelligence, and every refinement in that system strips away uncertainty for the companies placing billion-dollar bets downstream.

The pattern is clear for anyone paying attention, specialization compounds while generalization dilutes, and while others chase broader service maps, Celerion focused on the exact decision points that determine whether a drug advances or stalls, building an edge that doesn’t rely on noise, only outcomes.

H.I.G. Capital exits and THL Partners steps in, but the thesis holds steady, early answers carry disproportionate value, and companies that can deliver them consistently tend to find themselves in rooms where the biggest decisions get made.